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ABSTRACT 
Objective: Assess if a classroom-based pharmacy education service for hospitalized headache patients newly prescribed a 
monoamine oxidase inhibitor (MAOI) results in, 1) higher self-perceived medication knowledge, or 2) lower perceived risk of using 
MAOIs. 
Subjects: Individuals admitted to an inpatient headache unit over a five month period 
Methods: Patient survey administered before and after the education service to any patient newly prescribed an MAOI.   
Results: Seventy-eight individuals completed the study. Paired-samples t-tests showed that for each of the four items related to self-
perceived medication knowledge, the scores reflected higher knowledge after the MAOI class compared to before the class (p < 0.05). 
For three out of the four items related to perceived risk of using MAOIs, the scores reflected a lower level of perceived risk after the 
MAOI class compared to before the class (p < 0.05). One item did not significantly change: “The MAOI prescribed for me is just as 
good as other products available for treating headache.” 
Conclusion: Our results demonstrate a pharmacist-conducted, classroom-based teaching method for newly prescribed MAOI patients 
can result in higher self-perceived medication knowledge and lower perceived risks.   
 
 
INTRODUCTION 
 
Among hospitalized patients, lack of medication education is 
a key contributor to non-adherence, misuse of prescribed 
drugs, and medication errors and costs society billions of 
dollars.
1,2
  To help address these issues in 2005 the American 
Society of Health Systems Pharmacy (ASHP) established their 
“2015 Initiative”.
3
    One of this project’s objectives is “by 
2015, 75% of hospital inpatients discharged with highly 
complex and high-risk medication regimens will receive 
discharge medication counseling by a pharmacist.”  This 
objective will undoubtedly require a resource commitment 
(i.e. labor) above present-day levels, thus education methods 
that optimize the number of patients instructed in a given 
amount of time are essential.   
 
Herein, we describe how classroom-based patient-education 
affected headache sufferers’ medication perceptions. 
Specifically, our objectives were to determine whether 
classroom-based, pharmacist-conducted education services 
result in, 1) higher self-perceived medication knowledge of 
monoamine oxidase inhibitors (MAOI), or 2) lower perceived 
risk of using MAOIs.  We focused on patients’ perceptions 
about their knowledge and risks because these perceptions 
(and not absolute knowledge or risk per se) affect patients’ 
willingness to consume MAOIs. 
 
Headache Unit Description 
Chronic daily headache (CDH), or headache four or more  
hours per day on 15 or more days per month, affects 4% of 
the general population and causes significant patient 
suffering, straining health care recourses, and poses 
particular treatment dilemmas.
4-6
  Current guidelines 
recommend inpatient admission of refractory headache 
sufferers for multiple reasons, including severe dehydration, 
diagnostic suspicion of organic etiology, status migraine, 
dependence on analgesics, ergots, opiates, barbiturates, or 
tranquilizers, failed outpatient detoxification for which 
inpatient pain and psychiatric management may be 
necessary, and initiation of drugs that may cause significant 
adverse events (e.g. MAOIs).
7
  Annually, the Diamond 
Headache Clinic Inpatient Unit (unit) admits approximately 
1200 CDH individuals, with admissions occurring every day of 
the week for an average seven day length of stay. 
 
The utility of MAOIs for CDH was first reported decades ago.
8-
10
  Despite this success, most clinicians remain reluctant to 
prescribe “risky” MAOIs due to fears of hypertensive crisis, 
serotonin syndrome, harsh dietary restrictions, and other 
hazards.  The foundations of these fears are poorly 
documented and these events’ actual occurrences are 
infrequent, treatable, and rarely result in sustained patient 
harm.
11-15
  Additionally, patients have misconceptions formed 
as a result of negative comments from health care providers 
or from other information sources such as the internet.   
 
 
Annually, the unit initiates MAOI therapy for approximately  
Original Research POLICY 
 
http://z.umn.edu/INNOVATIONS                              2010, Vol. 1, No. 1, Article 5                      INNOVATIONS in pharmacy   2 
 
300 CDH individuals, utilizing either phenelzine or 
isocarboxazide, whichever the physician prefers.  Prior to 
discharge, patients receive the MAOI for a minimum of three 
days.  Also, they attend a weekly class to learn the drug’s 
proper role and precautions; as part of a comprehensive 
treatment approach, the unit has a dedicated classroom 
hosting various weekly classes conducted by a dietitian, a 
physician, a physical therapist, psychologists, the Director of 
Nursing, biofeedback technicians, and a pharmacist.   
 
METHODS 
 
The study was approved by the University of Minnesota’s 
Human Subjects Review committee.  A Before-After Quasi-
Experimental Design was employed and patients received the 
survey questions as outlined below.  Over a five-month span, 
any patient newly prescribed an MAOI was eligible to 
participate.  Any individuals who had previously received 
MAOI education (n=27) were ineligible.  As per established 
procedure, during weekdays the pharmacist identified new 
MAOI patients and reminded them about Wednesday’s 60-
minute class as well as sought their enrollment.  Patients 
admitted on weekends were seen the subsequent Monday.  
Two identical surveys, administered before and after the 
class, were used as data collection instruments. Demographic 
information was collected to help describe the sample and 
interpret results.  The surveys included four items that 
measured aspects of perceived knowledge and four items 
that measured aspects of perceived risk associated with using 
MAOIs.
16-18
  For the measurement of perceived risk, we 
focused on assessing a person’s belief about perils associated 
with the product’s performance. Performance risk is related 
to the uncertainty and consequence of a product not 
functioning at some expected level.  Table 1 contains 
questions used for this study. 
 
During initial enrollment, individuals received written and 
verbal instructions regarding the survey’s purpose, voluntary 
nature, anonymity, and lack of impact on their care.  Patients’ 
questions regarding the study were addressed during this 
enrollment session, but specific drug questions were deferred 
until the class.  Those agreeing to participate were then 
administered the first questionnaire.  Patients were allowed 
to complete the requested information privately, to return 
the form at their convenience prior to class, and were 
purposely not informed that the survey would be re-
administered.    
 
To help control for testing effect bias, a minimum of 24 hours 
elapsed after the class before the pharmacist re-visited MAOI 
patients to seek their enrollment in the post-survey portion, 
again explaining the survey’s purpose, anonymity, voluntary  
nature, and lack of impact on their care. Patients could then 
complete the survey privately and return it anytime prior to 
discharge.  Each pre-class and post-class survey was uniquely 
numbered to allow a mechanism to ensure that intra-patient 
response comparisons were performed.  
 
The same pharmacist taught all classes, utilizing the Indian 
Health Service counseling technique of patients 
demonstrating they can answer three essential questions: 
What is the medication for? How will you take the 
medication? What should you expect?  The pharmacist 
explained key concepts for chronic headache patients 
including the role of MAOIs as preventive agents, how MAOIs 
are believed to interrupt headache pathology, and the need 
to utilize these drugs at least four to six weeks prior to 
assessing effectiveness.  Management principles for common 
adverse-effects (AE) were discussed and the treatment 
options for hypertensive crisis were specifically explained.   
Potential drug interactions were reviewed and the rationale 
for a Medic-alert bracelet was explained.  Patients could ask 
questions during the class and were allotted a portion of time 
specifically for discussions at the end of class.   
Besides pharmacy education, all patients were required to 
attend a 60-minute class taught every Friday by a dietitian 
regarding the current food recommendations for MAOIs, 
which is liberal in comparison to historically restrictive MAOI 
guidelines.  Though the diet class was not a component of our 
study, we suspect it contributed to patients’ overall MAOI 
knowledge. 
 
Data were entered into a computer using SPSS, Inc. statistical 
software for analysis. Descriptive statistics and the paired-
samples t-test were used for compare the before and after 
class results. The significance level for statistical tests was set 
at 0.05. 
 
RESULTS 
 
All 78 eligible patients agreed to participate.  Of these 
individuals, 77% were female and 82% had more than a high 
school education.  Their average age was 40 years (range = 18 
to 59).  Admission histories revealed that the typical 
participant used five prescription medications per day, with 
four of these being used for headache. Forty percent of the 
sample members used one or more over-the-counter (OTC) 
medications daily and 21% of the sample members used one 
or more OTC medications for headache. 
 
Table 2 shows results for the paired-samples t-tests for items  
related to self-perceived medication knowledge of MAOIs and 
items related to perceived risk associated with using MAOIs. 
For each of the four items related to self-perceived  
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medication knowledge, the scores reflected higher 
knowledge after the MAOI class compared to before the 
class. For three out of the four items related to perceived risk 
of using MAOIs, the scores reflected a lower level of 
perceived risk after the MAOI class compared to before the 
class. One item did not significantly change: “The MAOI 
prescribed for me is just as good as other products available 
for treating headache.” 
 
Perceived Knowledge about MAOIs 
For the first item related to perceived knowledge about 
MAOIs (I feel very knowledgeable about MAOIs) scores 
changed significantly from an average of 2.2 before the class 
to 5.3 after the class (rating scale was 1 = very strongly 
disagree to 7 = very strongly agree). Scores for this item 
increased in agreement for 75 out of the 78 study subjects 
(96%), remained the same for one person (1%), and 
decreased for two people (3%). For the second item (If a 
friend asked me about MAOIs, I could give him or her advice 
about them), the average score increased from 2.0 to 4.7. For 
this item, 70 (89%) of the respondents had scores that 
increased in agreement after the class, six (8%) remained 
unchanged, and two (3%) decreased. For the third item (I 
know enough about MAOIs so that I can make wise decisions 
about using them) average scores increased from 2.2 to 5.4. 
Seventy-two (92%) of the respondents had scores that 
increased in agreement after the class, four (5%) remained 
unchanged, and two (3%) decreased in agreement. The final 
item related to perceived knowledge (I feel very confident 
about my ability to use MAOIs correctly) increased from a 
score of 3.1 to 5.6 after the class. For this item, 65 (83%) of 
the respondents had an increase in their score, 12% of the 
scores remained unchanged, and 5% of the scores decreased. 
 
Perceived Risk Associated with Using MAOIs 
For the first item related to perceived risk associated with 
using MAOIs (I am very sure that the MAOI prescribed for me 
will help me feel better), the average score increased from 
3.9 before the class to 4.6 after the class. For this item, 35 
(45%) of the respondents’ scores increased, 35 (45%) of the 
scores remained unchanged, and eight (10%) decreased in 
agreement after the class. For the second item (There is a lot 
of risk involved in using the MAOI prescribed for me), scores 
decreased from 4.4 before the class to 3.6 after the class. For 
this item, eight (10%) of the respondents’ scores increased, 
19 (25%) remained unchanged, and 51 (65%) decreased. The 
third item (The MAOI prescribed for me is just as good as 
other products available for treating headache) exhibited no 
change in its average score before or after the class. For this 
item, 44 (56%) of the respondents had no change in their 
before and after scores, 17 (22%) exhibited a decrease in  
scores, and 17 (22%) exhibited an increase in scores. The final 
item related to perceived risk (The MAOI prescribed for me 
will perform as expected) had a slight increase in agreement 
level from 4.3 before the class to 4.5 after the class (p = 0.02). 
For this item, 18 (23%) of the respondents had an increase in 
their scores, 52 (67%) had no change in score, and 8 (10%) 
had a decrease in score.   
 
DISCUSSION 
 
To the best of our knowledge, this is the first attempt to 
measure the benefits of patient education for people 
prescribed MAOIs, drugs mired in fear and misconceptions.  
Our results show that pharmacist-conducted classroom 
education increased self-perceived MAOI knowledge and 
lowered self-perceived MAOI risk.  We believe these changes 
will translate into a greater self-efficacy for patients in terms 
of drug regimen adherence and side effect monitoring, 
increasing the probability of positive therapeutic outcomes. 
 
We note with great interest that our sample’s view of MAOIs 
in comparison to other medications did not change (“the 
MAOI prescribed for me is just as good as other products 
available for treating headache), suggesting these individuals 
still harbor reservations about MAOI use and might prefer a 
different drug.  Yet, once prescribed an MAOI, our other 
results demonstrated that a pharmacist’s education instilled a 
less negative, if not favorable, patient perspective of these 
agents.   
 
Of important note, nearly half of the sample appears to be 
withholding judgment of an MAOI’s ability to “help me feel 
better” until after an adequate trial of the medication.  We 
interpret this as illustrating patients’ awareness that drugs 
can affect people differently, thus they adopt a wait-and-see 
attitude as to how the MAOI will impact them individually.   
 
We suspect patients’ improved understanding of MAOIs 
resulted from multiple factors.  Patients undoubtedly 
benefited from speaking with a pharmacist with extensive 
knowledge regarding MAOIs.  Conducting these counseling 
sessions in a classroom environment was, in all probability, 
advantageous as patients gained from listening to the 
questions and experiences of other individuals.   
 
The results of this study enhance our previous research 
concluding that classroom-based counseling of hospitalized 
headache sufferers can achieve high patient satisfaction with 
minimal strain on personnel resources.
19
   Studies examining 
classroom-based education for other illnesses (e.g. diabetes) 
have also demonstrated favorable outcomes.
20
   Based on  
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these studies, we propose that classroom-based services are 
a viable option towards achieving expanded hospitalized-
patient education, either for high risk medications (e.g. 
MAOIs, warfarin, insulin) or for specific patient populations 
(e.g. diabetics, heart failure).  Classroom based counseling 
can also address inadequate education issues among 
hospitalized patients raised in other studies.
1,2,20
   In 
particular, classes maximize the number of patients a 
pharmacist can educate in a given period of time, minimizing 
labor costs.  This method provides an approach towards 2015 
Initiative’s goals and further research regarding classroom-
based pharmacists’ counseling services in hospitals is 
warranted.  
 
LIMITATIONS 
 
Our results should be viewed in light of the study’s 
limitations.  MAOI therapy for CDH typically spans months to 
years.  We measured the immediate, but vital, impact of our 
service on patients’ perceptions when beginning an MAOI, 
thus our results do not demonstrate long-term benefits.  A 
few patients’ scores did not change, while a few others 
indicated that post-class they had less MOAI knowledge or 
perceived more risk.  This may have resulted from simply 
circling the wrong response, an insensitive scale system, or 
the lecture may have left some patients, who prior to class 
were convinced that they understood MAOIs, feeling their 
comprehension of this drug was actually lacking.   
Examining patients’ perceptions of MAOIs is uncharted 
research, thus we had to design the questions of our survey, 
which were based on published work examining other 
medications, but have not performed any validation studies.   
 
Lastly, classroom-based pharmacy counseling is not a 
universal hospital service, thus our affirmative results may be 
partly or wholly explained by patients’ positive experience 
with this relatively novel assistance.   
 
CONCLUSIONS 
 
Pharmacist conducted classes increased patients’ self-
perceived knowledge and lowered perceived risk upon 
initiation of an MAOI. Continued follow-up is recommended 
to help individuals make decisions about therapy as they 
experience both the benefits and adverse effects that are 
unique to each patient.  Expansion of classroom-based 
pharmacy services within hospitals merits additional 
research. 
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Table 1 
 
SELF-PERCEIVED KNOWLEDGE 
 
1 = very strongly disagree to 7 = very strongly agree 
 
a. I feel very knowledgeable about MAOIs. 
 
b. If a friend asked me about MAOIs, I could give him or her advice about them.  
 
c. I know enough about MAOIs so that I can make wise decisions about using them. 
 
d. I feel very confident about my ability to use MAOIs correctly. 
 
 
PERCEIVED RISK 
 
1 = very strongly disagree to 7 = very strongly agree 
 
a. I am very sure that the MAOI prescribed for me will help me feel better. 
 
b. There is a lot of risk involved in using the MAOI prescribed for me. 
 
a. The MAIO prescribed for me is just as good as other products available for treating headache.  
 
b. The MAOI prescribed for me will perform as expected. 
 
 
DEMOGRAPHICS 
 
a. What is your gender?  _____ male  _____ female 
 
b. What is your age?  ______ years 
 
c. What is the highest level of education you have completed? _____ high school or less 
       _____ more than high school 
 
d. How many prescription medications do you use daily? ______ prescription drugs 
 
e. Of these prescription medications, how many do you use for headache?  _____ drugs 
 
f. How many non-prescription medications do you use daily?  _______ non-prescription drugs 
 
g. Of these non-prescription medications, how many do you use for headache? _____ drugs 
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Table 2 
Paired-samples t-tests for items related to perceived knowledge and perceived risk for MAOIs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Items were rated from 1 = very strongly disagree to 7 = very strongly agree, with 4 = neutral.  
Results are reported as mean and (standard error of the mean) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Item Pre – Score Post - Score Paired-samples 
t-test p-value 
Perceived Knowledge about MAOIs    
I feel very knowledgeable about MAOIs. 2.2 (0.15) 5.3 (0.09) <0.001 
If a friend asked me about MAOIs, I could give him or her 
advice about them. 
2.0 (0.15) 4.7 (0.13) < 0.001 
I know enough about MAOIs so that I can make wise 
decisions about using them. 
2.2 (0.16) 5.4 (0.09) < 0.001 
I feel very confident about my ability to use MAOIs 
correctly. 
3.1 (0.22) 5.6 (0.10) < 0.001 
    
Perceived Risk associated with using MAOIs    
I am very sure that the MAOI prescribed for me will help 
me feel better. 
3.9 (0.15) 4.6 (0.11) < 0.001 
There is a lot of risk involved in using the MAOI prescribed 
for me. 
4.4 (0.11) 3.6 (0.14) < 0.001 
The MAIO prescribed for me is just as good as other 
products available for treating headache. 
3.6 (0.13) 3.6 (0.15) 0.92 
The MAOI prescribed for me will perform as expected. 4.3 (0.08) 4.5 (0.10) 0.02 
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